603 related articles for article (PubMed ID: 26416734)
1. HIV-1 Nef promotes infection by excluding SERINC5 from virion incorporation.
Rosa A; Chande A; Ziglio S; De Sanctis V; Bertorelli R; Goh SL; McCauley SM; Nowosielska A; Antonarakis SE; Luban J; Santoni FA; Pizzato M
Nature; 2015 Oct; 526(7572):212-7. PubMed ID: 26416734
[TBL] [Abstract][Full Text] [Related]
2. SERINC3 and SERINC5 restrict HIV-1 infectivity and are counteracted by Nef.
Usami Y; Wu Y; Göttlinger HG
Nature; 2015 Oct; 526(7572):218-23. PubMed ID: 26416733
[TBL] [Abstract][Full Text] [Related]
3. HIV-1 Nef Antagonizes SERINC5 Restriction by Downregulation of SERINC5 via the Endosome/Lysosome System.
Shi J; Xiong R; Zhou T; Su P; Zhang X; Qiu X; Li H; Li S; Yu C; Wang B; Ding C; Smithgall TE; Zheng YH
J Virol; 2018 Jun; 92(11):. PubMed ID: 29514909
[TBL] [Abstract][Full Text] [Related]
4. Potent Enhancement of HIV-1 Replication by Nef in the Absence of SERINC3 and SERINC5.
Wu Y; Olety B; Weiss ER; Popova E; Yamanaka H; Göttlinger H
mBio; 2019 Jun; 10(3):. PubMed ID: 31186327
[TBL] [Abstract][Full Text] [Related]
5. The Antagonism of HIV-1 Nef to SERINC5 Particle Infectivity Restriction Involves the Counteraction of Virion-Associated Pools of the Restriction Factor.
Trautz B; Pierini V; Wombacher R; Stolp B; Chase AJ; Pizzato M; Fackler OT
J Virol; 2016 Dec; 90(23):10915-10927. PubMed ID: 27681140
[TBL] [Abstract][Full Text] [Related]
6. An N-Glycosylated Form of SERINC5 Is Specifically Incorporated into HIV-1 Virions.
Sharma S; Lewinski MK; Guatelli J
J Virol; 2018 Nov; 92(22):. PubMed ID: 30158294
[TBL] [Abstract][Full Text] [Related]
7. Nef homodimers down-regulate SERINC5 by AP-2-mediated endocytosis to promote HIV-1 infectivity.
Staudt RP; Smithgall TE
J Biol Chem; 2020 Nov; 295(46):15540-15552. PubMed ID: 32873704
[TBL] [Abstract][Full Text] [Related]
8. The host-cell restriction factor SERINC5 restricts HIV-1 infectivity without altering the lipid composition and organization of viral particles.
Trautz B; Wiedemann H; Lüchtenborg C; Pierini V; Kranich J; Glass B; Kräusslich HG; Brocker T; Pizzato M; Ruggieri A; Brügger B; Fackler OT
J Biol Chem; 2017 Aug; 292(33):13702-13713. PubMed ID: 28659343
[TBL] [Abstract][Full Text] [Related]
9. Effect of HIV-1 Env on SERINC5 Antagonism.
Beitari S; Ding S; Pan Q; Finzi A; Liang C
J Virol; 2017 Feb; 91(4):. PubMed ID: 27928004
[TBL] [Abstract][Full Text] [Related]
10. Influence of Different Glycoproteins and of the Virion Core on SERINC5 Antiviral Activity.
Diehl WE; Guney MH; Vanzo T; Kyawe PP; White JM; Pizzato M; Luban J
Viruses; 2021 Jun; 13(7):. PubMed ID: 34209034
[TBL] [Abstract][Full Text] [Related]
11. SERINC5 Can Enhance Proinflammatory Cytokine Production by Primary Human Myeloid Cells in Response to Challenge with HIV-1 Particles.
Pierini V; Gallucci L; Stürzel CM; Kirchhoff F; Fackler OT
J Virol; 2021 Apr; 95(9):. PubMed ID: 33597208
[TBL] [Abstract][Full Text] [Related]
12. Spotlight on HIV-1 Nef: SERINC3 and SERINC5 Identified as Restriction Factors Antagonized by the Pathogenesis Factor.
Fackler OT
Viruses; 2015 Dec; 7(12):6730-8. PubMed ID: 26703715
[TBL] [Abstract][Full Text] [Related]
13. Characterization of Endogenous SERINC5 Protein as Anti-HIV-1 Factor.
Passos V; Zillinger T; Casartelli N; Wachs AS; Xu S; Malassa A; Steppich K; Schilling H; Franz S; Todt D; Steinmann E; Sutter K; Dittmer U; Bohne J; Schwartz O; Barchet W; Goffinet C
J Virol; 2019 Dec; 93(24):. PubMed ID: 31597782
[TBL] [Abstract][Full Text] [Related]
14. Identification of SERINC5-001 as the Predominant Spliced Isoform for HIV-1 Restriction.
Zhang X; Zhou T; Yang J; Lin Y; Shi J; Zhang X; Frabutt DA; Zeng X; Li S; Venta PJ; Zheng YH
J Virol; 2017 May; 91(10):. PubMed ID: 28275190
[TBL] [Abstract][Full Text] [Related]
15. TIM-mediated inhibition of HIV-1 release is antagonized by Nef but potentiated by SERINC proteins.
Li M; Waheed AA; Yu J; Zeng C; Chen HY; Zheng YM; Feizpour A; Reinhard BM; Gummuluru S; Lin S; Freed EO; Liu SL
Proc Natl Acad Sci U S A; 2019 Mar; 116(12):5705-5714. PubMed ID: 30842281
[TBL] [Abstract][Full Text] [Related]
16. HIV: Antiviral action countered by Nef.
Aiken C
Nature; 2015 Oct; 526(7572):202-3. PubMed ID: 26416750
[No Abstract] [Full Text] [Related]
17. Viral pathogenesis: HIV-1 Nef targets restriction factors.
Nunes-Alves C
Nat Rev Microbiol; 2015 Nov; 13(11):660-1. PubMed ID: 26456923
[No Abstract] [Full Text] [Related]
18. HIV-1 Nef hijacks both exocytic and endocytic pathways of host intracellular trafficking through differential regulation of Rab GTPases.
Kumari S; Dash PK; Kumari T; Guo ML; Ghosh JK; Buch SJ; Tripathi RK
Biol Cell; 2022 Oct; 114(10):276-292. PubMed ID: 35713972
[TBL] [Abstract][Full Text] [Related]
19. A Conserved Acidic-Cluster Motif in SERINC5 Confers Partial Resistance to Antagonism by HIV-1 Nef.
Stoneham CA; Ramirez PW; Singh R; Suarez M; Debray A; Lim C; Jia X; Xiong Y; Guatelli J
J Virol; 2020 Mar; 94(7):. PubMed ID: 31941773
[TBL] [Abstract][Full Text] [Related]
20. An Amino Acid Polymorphism within the HIV-1 Nef Dileucine Motif Functionally Uncouples Cell Surface CD4 and SERINC5 Downregulation.
Mumby MJ; Johnson AL; Trothen SM; Edgar CR; Gibson R; Stathopulos PB; Arts EJ; Dikeakos JD
J Virol; 2021 Jul; 95(16):e0058821. PubMed ID: 34037423
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
